Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.

Vink FJ, Meijer CJLM, Clifford GM, Poljak M, Oštrbenk A, Petry KU, Rothe B, Bonde J, Pedersen H, de Sanjosé S, Torres M, Del Pino M, Quint WGV, Cuschieri K, Boada EA, van Trommel NE, Lissenberg-Witte BI, Floore AN, Hesselink AT, Steenbergen RDM, Bleeker MCG, Heideman DAM.

Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614. [Epub ahead of print]

PMID:
31390052
2.

Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study.

Floore A, Hesselink A, Oštrbenk A, Alcaniz E, Rothe B, Pedersen H, Torres Hortal M, Doorn S, Quint W, Petry KU, Poljak M, Cuschieri K, Bonde J, de Sanjosé S, Bleeker M, Heideman D.

J Clin Lab Anal. 2019 May;33(4):e22854. doi: 10.1002/jcla.22854. Epub 2019 Feb 13.

3.

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A.

Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22.

4.

Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature.

Delahaye LJ, Wehkamp D, Floore AN, Bernards R, Van't Veer LJ, Glas AM.

Per Med. 2013 Nov;10(8):801-811. doi: 10.2217/pme.13.88.

PMID:
29776281
5.

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

Groenendijk FH, Zwart W, Floore A, Akbari S, Bernards R.

Breast Cancer Res Treat. 2013 Aug;140(3):475-84. doi: 10.1007/s10549-013-2648-1. Epub 2013 Aug 4.

6.

Gene expression profiling guiding diagnosis and therapy of rare mammary-like anogenital gland carcinomas.

Gunvén P, Randén M, Elmberger G, Bozóky B, Floore A.

Med Oncol. 2012 Mar;29(1):127-32. doi: 10.1007/s12032-010-9769-8. Epub 2010 Dec 4.

PMID:
21132401
7.

Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site.

Soesan M, de Snoo F, Westerga J, Floore A, Bender R.

Neth J Med. 2010 Jan;68(1):50-1. No abstract available.

8.

Comparison of histopathological and gene expression-based typing of cancer of unknown primary.

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Virchows Arch. 2010 Jan;456(1):23-9. doi: 10.1007/s00428-009-0867-y. Epub 2009 Dec 10.

PMID:
20012089
9.

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ.

Ann Oncol. 2010 Apr;21(4):717-22. doi: 10.1093/annonc/mdp388. Epub 2009 Oct 13.

PMID:
19825882
10.

[Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Pathologe. 2009 Dec;30 Suppl 2:168-72. doi: 10.1007/s00292-009-1194-4. German.

PMID:
19756615
11.

A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility.

Roepman P, Schuurman A, Delahaye LJ, Witteveen AT, Floore AN, Glas AM.

BMC Med Genomics. 2009 Aug 12;2:52. doi: 10.1186/1755-8794-2-52.

12.

Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.

van Laar RK, Ma XJ, de Jong D, Wehkamp D, Floore AN, Warmoes MO, Simon I, Wang W, Erlander M, van't Veer LJ, Glas AM.

Int J Cancer. 2009 Sep 15;125(6):1390-7. doi: 10.1002/ijc.24504.

13.

An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.

Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N.

Clin Cancer Res. 2009 Jan 1;15(1):284-90. doi: 10.1158/1078-0432.CCR-08-1258.

14.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.

Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26.

PMID:
18819002
15.

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D.

J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969.

PMID:
18802156
16.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27.

PMID:
18661261
17.

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary.

Bridgewater J, van Laar R, Floore A, Van'T Veer L.

Br J Cancer. 2008 Apr 22;98(8):1425-30. doi: 10.1038/sj.bjc.6604315. Epub 2008 Apr 15.

18.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.

Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10.

PMID:
18042430
19.

Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools.

Ach RA, Floore A, Curry B, Lazar V, Glas AM, Pover R, Tsalenko A, Ripoche H, Cardoso F, d'Assignies MS, Bruhn L, Van't Veer LJ.

BMC Genomics. 2007 Jun 7;8:148.

20.

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ.

BMC Genomics. 2006 Oct 30;7:278.

21.

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium.

J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92.

PMID:
16954471
22.

Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van T Veer LJ, Menko FH.

Fam Cancer. 2006;5(2):169-74.

PMID:
16736287
23.

Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J.

Cancer Cell. 2004 Jun;5(6):597-605.

24.

Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?

Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H.

Cancer Res. 2004 Feb 1;64(3):840-3.

25.

IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer.

Broeks A, Urbanus JH, de Knijff P, Devilee P, Nicke M, Klöpper K, Dörk T, Floore AN, van't Veer LJ.

Hum Mutat. 2003 May;21(5):521-8.

PMID:
12673794
26.

Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.

Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ.

Int J Radiat Biol. 2000 May;76(5):693-8.

PMID:
10866292
27.

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ.

Am J Hum Genet. 2000 Feb;66(2):494-500.

28.

ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.

Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ.

Hum Mutat. 1998;12(5):330-7.

PMID:
9792409
29.
30.

Stabilization of the nuclear matrix by disulfide bridges: identification of matrix polypeptides that form disulfides.

Stuurman N, Floore A, Colen A, de Jong L, van Driel R.

Exp Cell Res. 1992 Jun;200(2):285-94.

PMID:
1572396
31.

A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies.

Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L, van Driel R.

J Cell Sci. 1992 Apr;101 ( Pt 4):773-84.

Supplemental Content

Loading ...
Support Center